Showing results (21-30 of 108) with videos related to

Sort By:
Pageof 11
Oncotarget|September 11, 2016
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenibAndrea Casadei Gardini, Emanuela Scarpi, Luca Faloppi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 22, 2013
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patientsAnnagiulia Gramenzi, Sara Tedeschi, Maria Chiara Cantarini, et al.
Digestive Diseases and Sciences|May 21, 2017
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular CarcinomaSerena De Matteis, Anna Maria Granato, Roberta Napolitano, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|August 9, 2021
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgeryMatteo Canale, Francesco Giuseppe Foschi, Pietro Andreone, et al.
Critical Reviews in Oncology/Hematology|August 12, 2018
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinomaMatteo Canale, Paola Ulivi, Francesco Giuseppe Foschi, et al.
Journal of Clinical Medicine|April 25, 2020
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population StudyMargherita Rimini, Andrea Casadei-Gardini, Alessandra Ravaioli, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 18, 2018
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antiviralsAndrea Casadei Gardini, Francesco Giuseppe Foschi, Fabio Conti, et al.
Internal and Emergency Medicine|March 29, 2024
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenibBernardo Stefanini, Francesco Tovoli, Franco Trevisani, et al.
Scientific Reports|February 18, 2017
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective studyAndrea Casadei Gardini, Flavia Foca, Mario Scartozzi, et al.
Oncotarget|October 15, 2017
Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic reviewAndrea Casadei Gardini, Daniele Santini, Giuseppe Aprile, et al.
Pageof 11